Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Arcturus Therapeutics Ltd (Arcturus), formerly Alcobra Ltd is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases with unmet medical needs. It discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery systems. Arcturus offers messenger RNA (mRNA), which can be used as protein replacement therapy to treat diseases caused by a lack of protein and by defective proteins such as cystic fibrosis. The companys pipeline products include Lunar-OTC, Lunar-CF, Lunar-Rare1, Lunar-Rare2, Lunar-HBV, Lunar-NASH, ARB-1467, among others. Its RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus is headquartered in San Diego, California, the US.

Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Arcturus Therapeutics Raises USD67.7 Million in Venture Financing 10
Partnerships 11
Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 11
Merger 12
Alcobra Merges with Arcturus Therapeutics 12
Equity Offering 14
Alcobra Raises USD41.5 Million in Public Offering of Shares 14
Alcobra Raises USD29.9 Million in Public Offering of Shares 16
Alcobra Completes Public Offering Of Shares For US$38 Million 18
Alcobra Completes IPO For US$25 Million 20
Acquisition 22
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 22
Arcturus Therapeutics Ltd - Key Competitors 23
Arcturus Therapeutics Ltd - Key Employees 24
Arcturus Therapeutics Ltd - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Strategy And Business Planning 26
Jun 23, 2017: Alcobra Updates On Its Review Of Strategic Alternatives 26
Financial Announcements 27
Nov 09, 2017: Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update 27
Aug 11, 2017: Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 30, 2017: Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update 29
Feb 15, 2017: Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 30
Corporate Communications 31
May 31, 2018: Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO 31
May 29, 2018: Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne 32
May 15, 2017: Alcobra Announces Leadership Update 34
Legal and Regulatory 35
May 23, 2018: Arcturus Therapeutics Comments on Court Ruling on Undisclosed Group Organized by Joseph E. Payne and his Associates in Violation of Regulation 13D 35
Product Approvals 36
Feb 06, 2017: Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List Of Tables


Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arcturus Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arcturus Therapeutics Raises USD67.7 Million in Venture Financing 10
Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 11
Alcobra Merges with Arcturus Therapeutics 12
Alcobra Raises USD41.5 Million in Public Offering of Shares 14
Alcobra Raises USD29.9 Million in Public Offering of Shares 16
Alcobra Completes Public Offering Of Shares For US$38 Million 18
Alcobra Completes IPO For US$25 Million 20
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 22
Arcturus Therapeutics Ltd, Key Competitors 23
Arcturus Therapeutics Ltd, Key Employees 24
Arcturus Therapeutics Ltd, Subsidiaries 25

List Of Figures


Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arcturus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Arcturus Therapeutics Ltd (Arcturus), formerly Alcobra Ltd is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases with unmet medical needs. It discovers and

USD 250 View Report

Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Arcturus Therapeutics Ltd (Arcturus), formerly Alcobra Ltd is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases with unmet medical needs. It discovers and

USD 250 View Report

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available